BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23587228)

  • 1. Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
    El-Arab LR; Swellam M; El Mahdy MM
    J Egypt Natl Canc Inst; 2012 Mar; 24(1):15-22. PubMed ID: 23587228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
    Montagna E; Cancello G; Bagnardi V; Pastrello D; Dellapasqua S; Perri G; Viale G; Veronesi P; Luini A; Intra M; Calleri A; Rampinelli C; Goldhirsch A; Bertolini F; Colleoni M
    Clin Breast Cancer; 2012 Jun; 12(3):207-14. PubMed ID: 22520733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.
    Colleoni M; Rocca A; Sandri MT; Zorzino L; Masci G; Nolè F; Peruzzotti G; Robertson C; Orlando L; Cinieri S; de BF; Viale G; Goldhirsch A
    Ann Oncol; 2002 Jan; 13(1):73-80. PubMed ID: 11863115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
    Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
    Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
    Wang Z; Lu J; Leaw S; Hong X; Wang J; Shao Z; Hu X
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):515-22. PubMed ID: 21874317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
    Dellapasqua S; Bertolini F; Bagnardi V; Campagnoli E; Scarano E; Torrisi R; Shaked Y; Mancuso P; Goldhirsch A; Rocca A; Pietri E; Colleoni M
    J Clin Oncol; 2008 Oct; 26(30):4899-905. PubMed ID: 18794539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
    Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
    J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.
    Colleoni M; Orlando L; Sanna G; Rocca A; Maisonneuve P; Peruzzotti G; Ghisini R; Sandri MT; Zorzino L; Nolè F; Viale G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):232-8. PubMed ID: 16322118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM).
    Orlando L; Lorusso V; Giotta F; Di Maio M; Schiavone P; Fedele P; Quaranta A; Caliolo C; Ciccarese M; Cinefra M; Romito S; Pisconti S; Prete SD; Aieta M; Rizzi D; Maiello E; Colucci G; Cinieri S
    Breast; 2020 Oct; 53():18-22. PubMed ID: 32540553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
    Mariani G; Petrelli F; Zambetti M; Moliterni A; Fasolo A; Marchiano A; Valagussa P; Gianni L
    Clin Breast Cancer; 2006 Oct; 7(4):321-5. PubMed ID: 17092399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
    Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer.
    Orlando L; Cardillo A; Rocca A; Balduzzi A; Ghisini R; Peruzzotti G; Goldhirsch A; D'Alessandro C; Cinieri S; Preda L; Colleoni M
    Anticancer Drugs; 2006 Sep; 17(8):961-7. PubMed ID: 16940806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
    Dellapasqua S; Bagnardi V; Bertolini F; Sandri MT; Pastrello D; Cancello G; Montagna E; Balduzzi A; Mancuso P; Luini A; Goldhirsch A; Colleoni M
    Breast; 2012 Jun; 21(3):309-13. PubMed ID: 22341133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
    Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage of capecitabine and cyclophosphamide combination therapy in patients with metastatic breast cancer.
    Ohno S; Mitsuyama S; Tamura K; Nishimura R; Tanaka M; Hamada Y; Kuroki S;
    Anticancer Res; 2007; 27(2):1009-13. PubMed ID: 17465235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Toxicity of Metronomic Chemotherapy in Metastatic Breast Cancer: Egyptian Experience.
    Hussein MM; Gaafar RM; Abdel-Warith AM; Ahmed WA; Allahloubi NMA; Salem SE; Abdel-Salam IM
    Clin Breast Cancer; 2017 Dec; 17(8):618-628. PubMed ID: 28625341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
    Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.